Design of an Implant for Long-Acting HIV Pre-Exposure Prophylaxis: Input from South African Health Care Providers

被引:23
作者
Krogstad, Emily A. [1 ,2 ]
Montgomery, Elizabeth T. [3 ]
Atujuna, Millicent [1 ]
Minnis, Alexandra M. [2 ]
O'Rourke, Shannon [2 ]
Ahmed, Khatija [4 ]
Bekker, Linda-Gail [1 ]
van der Straten, Ariane [2 ,5 ]
机构
[1] Univ Cape Town, Desmond Tutu HIV Ctr, Wernher Beit North Bldg,Anzio Rd, ZA-7705 Cape Town, South Africa
[2] RTI Int, Womens Global Hlth Imperat, San Francisco, CA USA
[3] RTI Int, Womens Global Hlth Imperat, Los Angeles, CA USA
[4] Setshaba Res Ctr, Soshanguve, South Africa
[5] Univ Calif San Francisco, Ctr AIDS Prevent Studies, San Francisco, CA 94143 USA
关键词
HIV pre-exposure prophylaxis; contraceptive; implant; health care providers; product development; South Africa; CONTRACEPTIVE IMPLANT; USER PERSPECTIVES; NXT; ACCEPTABILITY; CHALLENGES;
D O I
10.1089/apc.2018.0177
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Implants are in the pre-clinical stage for long-acting HIV pre-exposure prophylaxis (PrEP), with an opportunity to solicit end-users' feedback early in development. Health care providers (HCPs) have been key gatekeepers for contraceptive implant uptake, and uniquely understand both technical considerations and the social context of use. Given their influential role, we gathered South African HCP perspectives on contraceptive implant implementation and features of PrEP implant prototypes that may influence future provider and patient acceptability. We conducted in-depth interviews with 30 HCPs (20 nurses and 10 doctors) in Cape Town and Soshanguve, South Africa. Interviews were conducted by a bioengineer and later transcribed, coded, and analyzed for key themes. HCPs described health system barriers such as understaffed clinics and inadequate training on contraceptive implant removal as major influences to their PrEP implant design preferences. They preferred a PrEP implant that is long lasting (>6 months) to minimize patient-clinic interactions, biodegradable to avoid need for removal, and flexible (but still palpable in case of removal). Commenting on negative experiences with contraceptive implant rollout, they recommended prioritizing both HCP and community education on the PrEP implant, with emphasis on expected side effects, and planning ahead for adequate training of HCPs before rollout. Challenges experienced with past contraceptive implant rollout may taint perspectives on future PrEP implants and must be carefully considered during product development and planning for clinical studies. Particular consideration should be given to the health system context of future distribution, including staff who would be providing and monitoring implants.
引用
收藏
页码:157 / 166
页数:10
相关论文
共 33 条
[1]   Optimizing Delivery of HIV Preexposure Prophylaxis for Women in the United States [J].
Aaron, Erika ;
Blum, Cori ;
Seidman, Dominika ;
Hoyt, Mary Jo ;
Simone, Joanne ;
Sullivan, Meg ;
Smith, Dawn K. .
AIDS PATIENT CARE AND STDS, 2018, 32 (01) :16-23
[2]   Uptake and early removals of Implanon NXT in South Africa: Perceptions and attitudes of healthcare workers [J].
Adeagbo, O. A. ;
Mullick, S. ;
Pillay, D. ;
Chersich, M. F. ;
Morroni, C. ;
Naidoo, N. ;
Pleaner, M. ;
Rees, H. .
SAMJ SOUTH AFRICAN MEDICAL JOURNAL, 2017, 107 (10) :822-826
[3]  
[Anonymous], 2018, DED VERS 8 0 41 WEB
[4]   Aligning product development and user perspectives: social-behavioural dimensions of multipurpose prevention technologies [J].
Brady, M. ;
Tolley, E. .
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2014, 121 :70-78
[5]   Factors Associated with Use of Short-Term Pre-Exposure Prophylaxis for HIV Among Female Partners of Migrant Miners in Mozambique [J].
Falcao, Joana ;
Zerbe, Allison ;
Lahuerta, Maria ;
Baggaley, Rachel ;
Ahoua, Laurence ;
DiMattei, Pietro ;
Morales, Fernando ;
Ramiro, Isaias ;
El-Sadr, Wafaa M. .
AIDS PATIENT CARE AND STDS, 2017, 31 (12) :528-534
[6]  
Gatto G, 2018, P F5 C RETR OPP INF
[7]   Pharmacokinetics of Long-Acting Tenofovir Alafenamide (GS-7340) Subdermal Implant for HIV Prophylaxis [J].
Gunawardana, Manjula ;
Remedios-Chan, Mariana ;
Miller, Christine S. ;
Fanter, Rob ;
Yang, Flora ;
Marzinke, Mark A. ;
Hendrix, Craig W. ;
Beliveau, Martin ;
Moss, John A. ;
Smith, Thomas J. ;
Bauma, Marc M. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (07) :3913-3919
[8]  
Hruschka DJ., 2004, Field methods, V16, P307, DOI DOI 10.1177/1525822X04266540
[9]  
Intarcia Therapeutics Inc Company Website, REV HIV PREV CONV ME
[10]   Liftoff: The Blossoming of Contraceptive Implant Use in Africa [J].
Jacobstein, Roy .
GLOBAL HEALTH-SCIENCE AND PRACTICE, 2018, 6 (01) :17-39